TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04913545

Intervention type: DIAGNOSTIC_TEST
Intervention: using salivary miRNA (412,512)
Description: quantitative real time polymerase chain reaction to detect the salivary miRNAs 412,512) to indicate the malignant transformation in potientially malignant oral lesions.

Intervention type: DIAGNOSTIC_TEST
Intervention: using salivary miRNA (412,512)
Description: quantitative real time polymerase chain reaction to detect the salivary miRNAs 412,512) to indicate the malignant transformation in potientially malignant oral lesions.

Intervention type: DIAGNOSTIC_TEST
Intervention: using salivary miRNA (412,512)
Description: quantitative real time polymerase chain reaction to detect the salivary miRNAs 412,512) to indicate the malignant transformation in potientially malignant oral lesions.
Study: NCT01234324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin, Cisplatin, Capecitabine, Panitumumab
Description: Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle; Panitumumab: 9 mg/kg bodyweight, administered IV by an infusion pump through a peripheral line or catheter over 60 min +-15 min on day 1 of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin, Cisplatin, Capecitabine
Description: Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
Study: NCT01144845

Intervention type: PROCEDURE
Intervention: Thoracic surgery
Description: Thoracoscopy or anterior thoracotomy
Study: NCT03247686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RSLV-132
Description: RNase Fc fusion protein

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04473625

Intervention type: OTHER
Intervention: Stool Sample Collection
Description: Subjects participating in the study will provide a stool sample within 30 days of enrollment.

Intervention type: OTHER
Intervention: Stool Sample Collection
Description: Subjects participating in the study will provide a stool sample within 30 days of enrollment.

Intervention type: OTHER
Intervention: Stool Sample Collection
Description: Subjects participating in the study will provide a stool sample within 30 days of enrollment.

Intervention type: OTHER
Intervention: Stool Sample Collection
Description: Subjects participating in the study will provide a stool sample within 30 days of enrollment.

Intervention type: OTHER
Intervention: Stool Sample Collection
Description: Subjects participating in the study will provide a stool sample within 30 days of enrollment.
Study: NCT04252716

Intervention type: DEVICE
Intervention: OVD
Description: Intraocular administration

Intervention type: DEVICE
Intervention: OVD
Description: Intraocular administration
Study: NCT02874196

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard arthrography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual energy arthrography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthro-tomosynthesis
Study: NCT04727775

Intervention type: DRUG
Intervention: Favipiravir
Description: Antiviral drugs
Study: NCT02874196

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthro-tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery on painful prosthesis
Description: Possibly performed during 6 months from arthrography
Study: NCT01096745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Cisplatin
Description: D1,D8 Gemcitabine 1000mg/m2 + N/S 150cc miv over 30mins D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins repeated every 3weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, Cisplatin
Description: D1-14 S-1 40mg/m2 po bid D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins Repeated every 3 weeks
Study: NCT04506567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-J591
Description: Single cycle of fractionated dose of 225Ac-J591

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-HBED-CC injection
Description: 68Ga-PSMA-HBED-CC PET/CT before and after treatment

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-HBED-CC injection
Description: 68Ga-PSMA-HBED-CC PET/CT before and after treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-J591
Description: Single dose of 225Ac-J591 every 6 weeks x 4
Study: NCT04473625

Intervention type: OTHER
Intervention: Stool Sample Collection
Description: Subjects participating in the study will provide a stool sample within 30 days of enrollment.
Study: NCT04204096

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-DT (Multi-dose formulation)
Description: * Manufacturer: SK bioscience Co., Ltd.~* Dose formulation: 25 µg Vi polysaccharide /0.5 mL, presented in Type I glass vial (multi dose Vi-DT with preservative 2 PE)~* Mode of Administration: 0.5 mL by intramuscular injection in the left anterolateral thigh or left arm deltoid region in participants below 2 years of age, less dominant arm deltoid region in age group 2 to 45 years~* Storage Conditions: +2 to +8°C

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-DT (Single dose formulation)
Description: * Manufacturer: SK bioscience Co., Ltd.~* Dose formulation: 25 µg Vi polysaccharide /0.5 mL, presented in Type I glass vial (single dose Vi-DT without any preservative)~* Mode of Administration: 0.5 mL by intramuscular injection in the left anterolateral thigh or left arm deltoid region in participants below 2 years of age, less dominant arm deltoid region in age group 2-45 years~* Storage Conditions: +2 to +8°C

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Vaccine
Description: * For participant ≥ 1 year one dose of locally licensed Meningococcal conjugate vaccine will be administered~* For participants 6 months to 1 year one dose of locally licensed Meningococcal conjugate vaccine will be administered during the study and the next dose will be provided after the study unblinding at the completion of 6 months follow up of last subject.
Study: NCT01944553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ROSA™ robot
Description: The ROSA™ robot can assist in identifying the pedicle entry point and in controlling the screw trajectory through a system of continuous monitoring of patient motion. This process strengthens the accuracy of pedicle screws implantation.~Stabilisation in treatment for spine degenerative disease
Study: NCT03568604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasterone
Description: 6.5 vaginal insert prasterone (dehydroepiandrosterone)
Study: NCT02276625

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rabies vaccine
Description: Compare ID administration to IM administration. 1 visit schedule.
Study: NCT04727775

Intervention type: DRUG
Intervention: Favipiravir
Description: Antiviral drugs

Intervention type: DRUG
Intervention: Favipiravir
Description: Antiviral drugs
Study: NCT02276625

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rabies vaccine
Description: Compare ID administration to IM administration. 1 visit schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rabies vaccine
Description: Compare ID administration to IM administration. 1 visit schedule.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rabies vaccine
Description: Compare ID administration to IM administration. 1 visit schedule.
Study: NCT04453969

Intervention type: OTHER
Intervention: COVID-19
Description: Exposure of interest for this observational study is current COVID-19 positive status or COVID-19 positive status during pregnancy
Study: NCT01173861

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity counseling
Description: 20-30 minutes of face-to-face physical activity counseling using motivational interviewing followed by 3 20 minute telephone counseling sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity counseling
Description: 20-30 minutes of face-to-face physical activity counseling using motivational interviewing followed by 3 20 minute telephone counseling sessions.
Study: NCT03861611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Participants may be randomized to receive Ketorolac oral medication 10 mg, every 8 hours for 5 days as needed
Study: NCT02086617

Intervention type: OTHER
Group type: OTHER
Intervention: ultrasound of aorta
Study: NCT02369354

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TALKS Social Worker Intervention
Description: TALKS includes a video and book that describe patient and family experiences with talking about and considering live kidney transplantation. TALKS also includes a social worker meeting. Potential recipients meet with a transplant social worker for up to 60 minutes to identify potential barriers to considering or pursuing live donor kidney transplantation. They also are invited to have a second meeting with family and/or friends with the social worker for up to 60 minutes.
Study: NCT03861611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Participants may be randomized to receive Ibuprofen oral medication 600 mg, every 8 hours for 5 days as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Participants may be randomized to receive Diflofenac oral medication 50 mg, every 8 hours for 5 days as needed

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on National Institute of Arthritis and Musculoskeletal and Skin Diseases Handout on Health: Back Pain information

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on National Institute of Arthritis and Musculoskeletal and Skin Diseases Handout on Health: Back Pain information

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on National Institute of Arthritis and Musculoskeletal and Skin Diseases Handout on Health: Back Pain information
Study: NCT01335685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone tablets
Study: NCT01981759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: Participants will receive 10 administrations of 50 mg of D-Cycloserine by mouth one hour before CBT sessions, weekly, in weeks 3-12.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 12 weekly administrations of placebo by mouth 1 hour before CBT sessions, from weeks 1-12.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Participants will engage in a Cognitive Behavioral Therapy treatment plan designed for psychotic delusions. The program will consist of 12 one hour sessions, once weekly from study week 1-week 12.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Participants will engage in a Cognitive Behavioral Therapy treatment plan designed for psychotic delusions. The program will consist of 12 one hour sessions, once weekly from study week 1-week 12.
Study: NCT02369354

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TALKS Social Worker Intervention
Description: TALKS includes a video and book that describe patient and family experiences with talking about and considering live kidney transplantation. TALKS also includes a social worker meeting. Potential recipients meet with a transplant social worker for up to 60 minutes to identify potential barriers to considering or pursuing live donor kidney transplantation. They also are invited to have a second meeting with family and/or friends with the social worker for up to 60 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Financial Assistance Intervention
Description: The financial assistance intervention offers potential donors the ability to draw from a bank of $2100 to reimburse their costs related to being evaluated for live kidney donation or for donating a kidney. Costs include, but are not limited to: child care, travel, time off work, and other out of pocket expenses related to being evaluated to become a live kidney donor or to donating.
Study: NCT02199860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD II
Study: NCT01335685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone tablets
Study: NCT02199860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD II

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03269461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angiography and Optical Coherence Tomography evaluations
Description: coronary stent implantation followed by Angiography and Optical Coherence Tomography evaluations

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angiography and Optical Coherence Tomography evaluations
Description: coronary stent implantation followed by Angiography and Optical Coherence Tomography evaluations

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angiography and Optical Coherence Tomography evaluations
Description: coronary stent implantation followed by Angiography and Optical Coherence Tomography evaluations
Study: NCT01836224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Terlipressin (1.3mcg/min i.e 2mg over 24 hr to max of terlipressin 5.2mcg/min i.e. up to 8mg over 24hr) .The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure) \>65 .Terlipressin 2mg in 48ml,1ml=42mcg=0.67mg/min, max dose 8mg/day- 8ml/hr of infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Noradrenaline
Description: Noradrenaline 2amp (4000mcg in 50ml) at 6ml/hr = 7.5mcg/min and dose maximum 60mcg/min 24ml/hr double strength. The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)\>65
Study: NCT00993161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motriplate
Description: Number of contact couples

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motriplate
Description: Number of contact couples
Study: NCT00704912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat/Meal Replacement/Lifestyle Modification
Description: Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loestrin 1/20
Description: Patients will be started on a low dose containing OCP for a continuous 4 month period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination of treatments
Description: Medications will be administered as described for the other 2 arms.
Study: NCT02496962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: atorvastatin were taken daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo were taken daily for 5 days
Study: NCT02667327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granexin gel
Description: Granexin gel contains active pharmaceutical ingredient, aCT1 peptide, for topical application to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: The vehicle gel formulation is hydroxyethyl cellulose that does not contain the active aCT1 peptide. Vehicle gel will be applied topically to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
Study: NCT01630850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic islet cells (human, U. Chicago)
Description: Human allogenic islet cells. Immunosuppression may include remicade, thymoglobulin,prograf, solu-medrol, and cellcept. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraportal infusion of islet cells
Description: Intraportal infusion of islet cell through the portal vein in the liver.
Study: NCT02252887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Study: NCT02024282

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of C-reactive protein (CRP) point of care test

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of C-reactive protein (CRP) point of care test
Study: NCT01487161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006
Description: Single 3 mL intra-articular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006
Description: Single 3 mL intra-articular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006
Description: Single 3 mL intra-articular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCA IR
Description: Single 1 mL intra-articular injection
Study: NCT02486770

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aerucin 2.0mg/kg
Description: IV Aerucin 2.0 mg/kg over 1 hour

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aerucin 8.0mg/kg
Description: IV Aerucin 8.0 mg/kg over 1 hour

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aerucin 20.0 mg/kg
Description: IV Aerucin 20 mg/kg over 1 hour
Study: NCT03918291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Addition of whole-body vibration to squat training

Intervention type: OTHER
Group type: OTHER
Intervention: Squat training
Description: squatting exercises for 12 weeks, 3x/week
Study: NCT03493893

Intervention type: DEVICE
Intervention: Intermedullary nail
Description: investigate the clinical effects of these design changes from the use of three different IM nail designs in the management of extracapsular hip fractures.

Intervention type: DEVICE
Intervention: Intermedullary nail
Description: investigate the clinical effects of these design changes from the use of three different IM nail designs in the management of extracapsular hip fractures.

Intervention type: DEVICE
Intervention: Intermedullary nail
Description: investigate the clinical effects of these design changes from the use of three different IM nail designs in the management of extracapsular hip fractures.
Study: NCT04868071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: Exercise interventions were carried out over a total of 16 weeks in the mornings (08:00 am-12:00 am) under the supervision of at least two fitness instructors. Participants performed four exercises for lower limbs (Figure 9): 1st) squat on the chair, 2nd) seated unilateral hip flexion, 3rd) seated unilateral knee extension, and 4th) bilateral calf raise with 12-15 submaximal repetitions avoiding fatigue (i.e., inability to complete a repetition in a full range of motion). The number of sets was increased linearly during the first month, such that one set was performed in the 1st week, two sets in the 2nd week, 3 sets in the 3rd week, and 4 sets in the 4th week. Subsequently, participants performed the main exercise period. After a brief warm-up, participants performed the same exercises that were performed during the familiarization period using an adjustable weight vest and ankle weights (DOMYOS®, Shangai, China).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: Exercise interventions were carried out over a total of 16 weeks in the mornings (08:00 am-12:00 am) under the supervision of at least two fitness instructors. Participants performed four exercises for lower limbs (Figure 9): 1st) squat on the chair, 2nd) seated unilateral hip flexion, 3rd) seated unilateral knee extension, and 4th) bilateral calf raise with 12-15 submaximal repetitions avoiding fatigue (i.e., inability to complete a repetition in a full range of motion). The number of sets was increased linearly during the first month, such that one set was performed in the 1st week, two sets in the 2nd week, 3 sets in the 3rd week, and 4 sets in the 4th week. Subsequently, participants performed the main exercise period. After a brief warm-up, participants performed the same exercises that were performed during the familiarization period using an adjustable weight vest and ankle weights (DOMYOS®, Shangai, China).